A recent study has also demonstrated that resistance to a mammalian target of rapamycin (mTOR) inhibitor could be overcome with BCL-2 inhibition via ABT-737 treatment in a HNSCC cell line model [34]. The gene discussed is BCL2; the disease is head and neck squamous cell carcinoma.